Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer

Blockade of epidermal growth factor receptor (EGFR) activity has been a primary therapeutic target for non-small cell lung cancers (NSCLC). As patients with wild-type EGFR have demonstrated only modest benefit from EGFR tyrosine kinase inhibitors (TKIs), there is a need for additional therapeutic ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Howe, Grant A., Xiao, Bin, Zhao, Huijun, Al-Zahrani, Khalid N., Hasim, Mohamed S., Villeneuve, James, Sekhon, Harmanjatinder S., Goss, Glenwood D., Sabourin, Luc A., Dimitroulakos, Jim, Addison, Christina L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786279/
https://www.ncbi.nlm.nih.gov/pubmed/26962872
http://dx.doi.org/10.1371/journal.pone.0150567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786279/
https://www.ncbi.nlm.nih.gov/pubmed/26962872
http://dx.doi.org/10.1371/journal.pone.0150567

Ejemplares similares